Precisión diagnóstica del pico cepstral de mayor prominencia en el cepstrum suavizado (CPPS) en la detección de la disfonía en español

The smoothed cepstral peak prominence (CPPS) is an acoustic measure that can be calculated in both sustained vowels and continuous speech. The goal of this work is to find out the diagnostic accuracy of CPPS in the detection of dysphonia in Spanish. In this study 136 subjects with dysphonia and 47 healthy subjects participated. For each subject a sustained vowel and the reading of three phonetically balanced sentences were recorded. The CPPS was calculated with Praat using its default configuration (configuration 1), and also with the one used in the calculation of the Acoustic Voice Quality Index (configuration 2). Five experts perceptively assessed the voice of the subjects in the sample by means of the GRABS scale. The CPPS has a great power of discrimination between the normal and the pathological voice, whether it is calculated from the sustained vowel /a/ (AROC[config. 1] = 0.863 and AROC[config. 2] = 0.841) or whether it is calculated from the sentences (AROC[config. 1] = 0.884 and AROC[config. 2] = 0.866). The results confirm that CPPS is a valid acoustic measurement to detect dysphonia in the Spanish language.Los parámetros derivados de la métrica cepstral son cada vez más utilizados en la evaluación acústica de la voz, ya sea como medidas únicas o como parte de índices multivariados. El pico cepstral de mayor prominencia en el cepstrum suavizado (CPPS) ha demostrado en multitud de estudios ser la única medida acústica con la suficiente validez concurrente en la evaluación de la severidad de las alteraciones de la voz tanto en muestras de vocal sostenida como en muestras de habla continua. El objetivo de este trabajo es conocer la precisión diagnóstica del CPPS en la detección de la disfonía en español. Se utilizó la configuración que viene por defecto en Praat y la usada en el cálculo del Acoustic Voice Quality Index. Los resultados confirman que el CPPS es una medida acústica válida para detectar la disfonía en español tanto con vocal sostenida como con frases

Chondroid Tumors: Review of Salient Imaging Features and Update on the WHO Classification

Chondrogenic tumors are typically well recognized on radiographs, but differentiation between benign and malignant cartilaginous lesions can be difficult both for the radiologist and for the pathologist. Diagnosis is based on a combination of clinical, radiological and histological findings. While treatment of benign lesions does not require surgery, the only curative treatment for chondrosarcoma is resection. This article (1) emphasizes the update of the WHO classification and its diagnostic and clinical effects; (2) describes the imaging features of the various types of cartilaginous tumors, highlighting findings that can help differentiate benign from malignant lesions; (3) presents differential diagnoses; and (4) provides pathologic correlation. We attempt to offer valuable clues in the approach to this vast entit

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.This study was funded by the Spanish Group for Research on Sarcoma (GEIS) and partially by PharmaMar. The authors would like to thank the GEIS data center for data management. The authors also thank the donors and the Hospital Universitario Virgen del Rocío—Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for part of the human specimens used in this study. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155)

Aplicación de la metodología aprendizaje-servicio en la asignatura "Clínica jurídica de acción social" de la Facultad de Derecho

Memoria ID-149. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2019-2020

Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection induces an exacerbated inflammation driven by innate immunity components. Dendritic cells (DCs) play a key role in the defense against viral infections, for instance plasmacytoid DCs (pDCs), have the capacity to produce vast amounts of interferon-alpha (IFN-α). In COVID-19 there is a deficit in DC numbers and IFN-α production, which has been associated with disease severity. In this work, we described that in addition to the DC deficiency, several DC activation and homing markers were altered in acute COVID-19 patients, which were associated with multiple inflammatory markers. Remarkably, previously hospitalized and nonhospitalized patients remained with decreased numbers of CD1c+ myeloid DCs and pDCs seven months after SARS-CoV-2 infection. Moreover, the expression of DC markers such as CD86 and CD4 were only restored in previously nonhospitalized patients, while no restoration of integrin β7 and indoleamine 2,3-dyoxigenase (IDO) levels were observed. These findings contribute to a better understanding of the immunological sequelae of COVID-19

Adaptación de la asignatura “Clínica Jurídica de Acción Social” a un modelo de Aprendizaje-servicio con docencia semipresencial u online

Memoria ID-102. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2020-2021

Clínica jurídica de acción social

Memoria ID-025. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2018-2019

Clínica jurídica de acción social

Memoria ID-0064. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2016-2017